2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.16B.01 UK and US Patient Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitors Treatments

EP.16B.01 UK and US Patient Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitors Treatments

Back to course

Pdf Summary

This study examines patient preferences and experiences with tyrosine kinase inhibitors (TKIs) for ALK-positive advanced non-small cell lung cancer (aNSCLC) in the US and UK. In both countries, the primary consideration for patients was overall survival and progression-free survival, despite adverse effects from treatments. Treatment-related adverse events like fatigue, weight gain, and cognitive issues were common, with slight differences in other symptoms experienced and prioritized between the regions. <br /><br />UK patients tended to be younger and had less experience with multiple TKIs compared to US patients. Although concerns varied slightly—with UK patients more worried about ocular toxicity while US patients were more concerned about hyperlipidemia—both groups showed willingness to tolerate adverse effects for increased treatment benefits.<br /><br />Improving quality of life and prevention or control of disease spread were significant factors in treatment decisions. Preventing brain metastases and ensuring treatment regimens were easy to follow were also crucial. Both US and UK patients valued shared decision-making with healthcare providers and often sought information independently to make informed choices about their treatment options.<br /><br />The research utilized qualitative interviews from 20 US and 10 UK patients between April 2023 and February 2024. Most participants had stable disease and had been on their current treatment for over a year. Patients without brain metastases were particularly concerned about its potential impact on their daily lives, such as driving.<br /><br />The study highlights the need for considering patient preferences to improve treatment satisfaction and outcomes, proposing the development of guidelines tailored to differing patient needs across regions. Additionally, further research is warranted to validate these qualitative findings and explore patient perspectives with larger, more diverse samples.

Asset Subtitle

Kenneth Culver

Meta Tag

Speaker Kenneth Culver

Topic Patient Advocacy

Keywords

tyrosine kinase inhibitors

ALK-positive

non-small cell lung cancer

patient preferences

treatment adverse effects

quality of life

shared decision-making

brain metastases

treatment guidelines

qualitative research